OncoMatch

OncoMatch/Clinical Trials/NCT05370430

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Is NCT05370430 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BAFFR-CAR T cells for relapsed or refractory b-cell non-hodgkin's lymphoma.

Phase 1RecruitingPeproMene Bio, Inc.NCT05370430Data as of Jun 2026

Treatment: BAFFR-CAR T cellsA Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

BAFFR-CAR T cells

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: TNFRSF13C overexpression

BAFF-R expression on lymphoma cells required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: allogeneic stem cell transplant

Prior allogeneic SCT

Cannot have received: autologous stem cell transplant

Exception: allowed if ≥ 6 months before leukapheresis

Autologous SCT < 6 months before leukapheresis

Lab requirements

Blood counts

anc ≥ 1000/μl, platelets ≥ 75,000/μl (exceptions for bm involvement)

Kidney function

crcl ≥ 50 ml/min

Liver function

bilirubin ≤ 1.5x uln (except gilbert's), ast/alt < 3x uln

Cardiac function

lvef ≥ 45%, qtcf ≤ 480 ms, o₂ saturation > 91% on room air

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope Medical Center · Duarte, California
  • Stanford University · Stanford, California
  • University of Kansas Hospital · Kansas City, Kansas
  • University of Minnesota · Minneapolis, Minnesota
  • Atrium Health Levine Cancer Institute - Morehead · Charlotte, North Carolina

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05370430 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant disqualifies patients from enrollment.

Does this trial require TNFRSF13C?

Yes, TNFRSF13C overexpression is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify